MAM
SLNO

Martingale Asset Management’s Soleno Therapeutics SLNO Stock Holding History

Martingale Asset Management’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,810
Closed -$269K – 856
2025
Q4 		$269K Sell
5,810
-900
-13% -$49.3K 0.01% 709
2025
Q3 		$454K Sell
6,710
-200
-3% -$14.8K 0.01% 628
2025
Q2 		$579K Sell
6,910
-18,067
-72% -$1.35M 0.01% 589
2025
Q1 		$1.78M Sell
24,977
-201
-0.8% -$9.79K 0.05% 323
2024
Q4 		$1.13M Buy
25,178
+3,203
+15% +$166K 0.03% 450
2024
Q3 		$1.11M Buy
+21,975
New +$1.05M 0.03% 436

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.19B AUM 14.29% 1-Year Est. Return

Martingale Asset Management's SLNO Position: Q1 2026 in Review

Martingale Asset Management sold out of Soleno Therapeutics (SLNO) in Q1 2026, closing a stake of 5,810 shares — an estimated $269K sold.

Martingale Asset Management first reported a position in SLNO in Q3 2024 and held it in 6 quarters. The position peaked at $1.78M in Q1 2025. 226 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

  • Martingale Asset Management reported no remaining Soleno Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Martingale Asset Management sold 5,810 Soleno Therapeutics shares in Q1 2026, an estimated $269K.
  • Martingale Asset Management first reported a position in Soleno Therapeutics in Q3 2024 and held it in 6 quarters.
  • Martingale Asset Management's Soleno Therapeutics position peaked at $1.78M in Q1 2025.
  • 226 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on Martingale Asset Management's 13F filing for Q1 2026, filed 13 May 2026.